SCOT Registry: Small Cell Lung Cancer Treatment and Outcome (SCOT)
|ClinicalTrials.gov Identifier: NCT00997061|
Recruitment Status : Completed
First Posted : October 16, 2009
Last Update Posted : February 3, 2014
The registry is an international, multicenter, observational registry of newly diagnosed patients with SCLC.
Data will be entered into an electronic CRF (eCRF) via Internet access. Treatment plan remains the responsibility of the patient's physician and data collected in this registry will reflect a "real world" approach of the diagnosis and treatment of patients with SCLC.
Approximately 60 centres in 13 countries will take part in this registry. It is expected that about 500 patients will be recruited during a period of 6 to 9 months according to the feasibility.
|Condition or disease||Intervention/treatment|
|Lung Cancer, Small Cell||Drug: HYCAMTIN|
|Study Type :||Observational|
|Actual Enrollment :||500 participants|
|Official Title:||SCOT Registry: Small Cell Lung Cancer Treatment and Outcome|
|Study Start Date :||November 2009|
|Primary Completion Date :||February 2012|
|Study Completion Date :||February 2012|
Observing patients on HYCAMTIN and other drugs for SCLC.
- Registry with disease, treatment and outcome data collected. [ Time Frame: 6-9mth recruitment period, 18mth study duration. ]
- survival rates [ Time Frame: 18 month period ]
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00997061
Show 61 Study Locations
|Study Director:||GSK Clinical Trials||GlaxoSmithKline|